ArticleScientific reports2025
The loss to follow-up of participants excluded from the NAMSAL trial: a retrospective cohort study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite advances in Human Immune Virus (HIV) treatment, loss to follow-up (LTFU) remains a challenge, particularly in sub-Saharan Africa. Understanding its predictors is vital to improve retention in care and hence, better treatment outcomes. While clinical trials result in better follow-up and possibly better treatment for the patients included, little data is available on those excluded. We aimed to assess the LTFU rate and associated factors among patients excluded from the New Antiretroviral and Monitoring Strategies in HIV-infected Adults in Low-income Countries (NAMSAL) trial. A hospital-based retrospective cohort study was conducted from December 2022 to July 2023 across three health facilities in Yaoundé, Cameroon. Data from 132 patients who were excluded from the NAMSAL trial was analyzed using R software. LTFU was defined as no recorded data for three months or more after missing scheduled visits. Kaplan-Meier estimates and Cox proportional hazards regression were used to describe and analyze LTFU rates and associated factors, with a p-value < 0.05 considered statistically significant. We analyzed data from 132 (51% male) participants excluded from the NAMSAL trial, with a median age of 34 (IQR: 23-51) years. Most participants were employed (63.6%) and single (72.7%). This population was mostly in WHO clinical stages 1 (37.1%) and 3 (33.3%), and 57.6% had baseline viral loads below 100,000 copies/mL. More than half (74, 56.1%) were LTFU over the study period. The median time to LTFU was 108 weeks. Cox regression analysis revealed that being female (aHR = 0.27, [95% CI 0.13-0.52]; p˂0.001) and having a high baseline viral load (aHR = 0.34, [95% CI 0.16-0.71]; p = 0.004) were associated with reduced LTFU risk. The high LTFU rate among excluded NAMSAL trial patients highlights the need for targeted retention strategies, particularly for male patients, patients with multiple comorbidities and advanced disease stages. These findings can inform interventions to improve HIV care retention in Cameroon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.